NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
06:39pm, Tuesday, 03'rd Jan 2023 Benzinga
Gainers
Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) gained 257
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
12:55pm, Tuesday, 03'rd Jan 2023 Benzinga
Gainers
Gorilla Technology Group Inc. (NASDAQ: GRRR) shares rose 162% to $21.30 in pre-market trading after jumping over 35% on Friday. Gorilla Technology recently said it is entering the MENA regio
Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
11:15am, Tuesday, 03'rd Jan 2023 Benzinga
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Gorilla Technology Group Inc. (NASDAQ: GRRR) shares surged 162% to $2
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
06:14pm, Thursday, 29'th Dec 2022 Benzinga
Gainers
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
Quotient Limited (NASDAQ: QTNT) shares jumped 124% to $0.5382 afte
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
08:01pm, Monday, 05'th Dec 2022 GlobeNewswire Inc.
SAN DIEGO, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) is pleased to announce the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
07:06pm, Tuesday, 29'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today released topline Phase I SAD/MAD study data of its oral main protease (Mpro) inhibitor, ST
360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
12:55pm, Monday, 14'th Nov 2022 Benzinga
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
HUTCHMED (China) Limited (NASDAQ: HCM) shares jumped 18.7% to $11.75 i
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis
08:02pm, Sunday, 13'th Nov 2022 GlobeNewswire Inc.
ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Op
ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opin
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”
07:45pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
Scilex Holding Company to Ring the Nasdaq Opening Bell on Friday, November 11, 2022 at 9:30 a.m. ET Scilex Holding Company to Ring the Nasdaq Opening Bell on Friday, November 11, 2022 at 9:30 a.m. ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
07:15pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
PALO ALTO and NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX and SCLXW), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”),
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits
02:29pm, Wednesday, 09'th Nov 2022
Sorrento Therapeutics has been in the limelight for all the wrong reasons. Its R&D is just a byproduct of its business.
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
01:05pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends
11:48am, Friday, 04'th Nov 2022
When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.
